Pazopanib improves progression-free survival without impairing HRQOL
(European Organisation for Research and Treatment of Cancer) Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 6, 2015 Category: Cancer & Oncology Source Type: news
Bevacizumab May Be Next Standard of Care for Mesothelioma
Discussions About Mesothelioma at ASCO Meeting
There were other abstracts involving mesothelioma presented at the ASCO, adding even more optimism about potential treatment advances.
Dr. Raffit Hassan, mesothelioma specialist from the National Cancer Institute, detailed results of a phase I trial involving immunotherapy drug CRS-207 in combination with standard chemotherapy.
Disease control was obtained in 30 of the 32 trial participants. There was partial response in 19 patients and stable disease in 11. CRS-207 is given by
vaccination. Median duration of response was 5 months and median progression-fr...
Source: Asbestos and Mesothelioma News - June 5, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news
First-Ever Survival Bump for Soft-Tissue Sarcoma
(MedPage Today) -- Treatment with eribulin increased survival by 2 months versus dacarbazine. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 4, 2015 Category: Hematology Source Type: news
PharmaMar announces new advances in oncology at ASCO 2015 for compounds YONDELIS® and PM1183
(Pharmamar) PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS® and PM1183 highlighting data in small cell lung cancer, soft tissue sarcoma, and mesothelioma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2015 Category: Cancer & Oncology Source Type: news
PharmaMar announces that its partner Taiho files NDA for Yondelis in Japan for soft-tissue sarcoma
(Pharmamar) The J-NDA is supported by a pivotal Phase 2 trial showing that in Japanese patients Yondelis (trabectedin) provided clinical benefit, resulting in a significantly superior median progression-free survival compared to best supportive care (5.6 versus 0.9 months). The NDA will receive priority review by regulatory agency and will seek approval for various subtypes of advanced soft-tissue sarcoma in Japan. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2015 Category: Cancer & Oncology Source Type: news
PharmaMar announces US partner Janssen files NDA for YONDELIS for soft-tissue sarcoma
(Pharmamar) Based on a phase 3 trial in which dacarbazine was used in the comparator arm, Janssen has submitted a NDA for YONDELIS (trabectedin) to the FDA for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma, who have received prior chemotherapy including an anthracycline. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2014 Category: Cancer & Oncology Source Type: news
Few High - Grade Soft Tissue Sarcoma Patients Receive Chemo
Percentage of STS patients receiving chemo driven by factors such as tumor size, income, facility type (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Orthopedics, Pharmacy, Journal, Source Type: news
Patient-Friendly Guide Offers Free Step-by-Step Information for People with Soft Tissue Sarcoma
NCCN Guidelines for Patients®: Soft Tissue Sarcoma, available free-of-charge at NCCN.org/patients, is designed to provide people with cancer and their caregivers state-of-the-art treatment information in easy-to-understand language.
FORT WASHINGTON, PA - People with various soft tissue sarcoma diagnoses need access to state-of-the-art treatment information in easy-to-understand language. The National Comprehensive Cancer Network® (NCCN®) has published the NCCN Guidelines for Patients®: Soft ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - September 18, 2014 Category: Cancer & Oncology Source Type: news
Soft Tissue Sarcoma Guidelines: Updated and 'Irradiated'Soft Tissue Sarcoma Guidelines: Updated and 'Irradiated'
With more than 12,000 cases and almost 5000 deaths yearly, soft-tissue sarcoma is owed greater attention, as revised guidelines and perspectives from experts attest. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 11, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
Overall survival benefit for patients with Stage III soft tissue sarcomas
The first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS) has been conducted, adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 30, 2014 Category: Science Source Type: news
Research shows overall survival benefit for patients with Stage III soft tissue sarcomas
(Fox Chase Cancer Center) Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2014 Category: Cancer & Oncology Source Type: news
CytRx begins Phase III study of aldoxorubicin to treat soft tissue sarcoma
US-based biopharmaceutical research and development firm CytRx has started a global Phase III clinical trial to assess the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS). (Source: Drug Development Technology)
Source: Drug Development Technology - March 26, 2014 Category: Pharmaceuticals Source Type: news
Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
A new study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor. The coordinator of this study says, "Our clinical trial was designed to compare combination treatment with doxorubicin and ifosfamide to treatment with doxorubicin alone, and our results show that the combination chemotherapy did not improve overall survival. So, if the goal of treatment is to control the disease, then administering doxorubicin alone is appropriate." (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 25, 2014 Category: Science Source Type: news
Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
(European Organisation for Research and Treatment of Cancer) An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2014 Category: Global & Universal Source Type: news
Responders, survivors on pazopanib characterized for advanced soft tissue sarcoma
An analysis has confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 10, 2014 Category: Science Source Type: news
